Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 32Colorectal Neoplasms 8Brain Neoplasms 7Stomach Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Meningeal Neoplasms 3HER2-positive Breast Cancer 3Rectal Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Diseases 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 100liposomal doxorubicin 100Cyclophosphamide 94Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 39Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × tucatinib × Clear all
NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡